AbbVie faces US antitrust claims over Humira
MLex Summary: A proposed US class action accuses AbbVie of conspiring to block biosimilar competition to its brand name drug Humira. According to the complaint, AbbVie entered into agreements with pharmacy...To view the full article, register now.
Already a subscriber? Click here to view full article